Pinato, David J., Gramenitskaya, Daria, Altmann, Daniel M., Boyton, Rosemary J., Mullish, Benjamin H., Marchesi, Julian R.  ORCID: https://orcid.org/0000-0002-7994-5239 and Bower, Mark
2019.
Antibiotic therapy and outcome from immune-checkpoint inhibitors.
Journal for ImmunoTherapy of Cancer
7
(1)
, 287.
10.1186/s40425-019-0775-x
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (547kB) | Preview |
Abstract
Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic mechanisms underlying the association with outcome are poorly understood. Perturbation of the gut microbiota, an increasingly well-characterized factor capable of influencing ICPI-mediated immune reconstitution, has been indicated as a putative mechanism to explain the adverse effects attributed to antibiotic exposure in the context of ICPI therapy. Prospective studies are required to validate antibiotic-mediated gut perturbations as a mechanism of ICPI refractoriness and guide the development of strategies to overcome this barrier to an effective delivery of anti-cancer immunotherapy.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Biosciences |
| ISSN: | 2051-1426 |
| Date of First Compliant Deposit: | 18 November 2019 |
| Date of Acceptance: | 9 October 2019 |
| Last Modified: | 08 May 2023 04:36 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/126920 |
Citation Data
Cited 77 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions